CAR T Therapy Shows High Remission Rates in Multiple Myeloma, Communication Improvements Reduce Risks
CAR T-cell therapy is delivering high remission rates for multiple myeloma patients, with improved handoff communication reducing infection risks. FDA-approved BCMA-targeting products show response rates from 72% to 98% in heavily pretreated patients.
A communication improvement intervention demonstrated that structured handoff tools can enhance coordination, reduce infection risk, and support better long-term outcomes in patients with multiple myeloma who have been treated with CAR T-cell therapy, according to a recent study presented during the 2026 Tandem Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research.
CAR T cell therapy is delivering unusually high remission rates for multiple myeloma patients. The FDA has signed off on BCMA-targeting CAR T products for people with relapsed or refractory multiple myeloma, and pivotal trials have reported very high response rates in heavily pretreated patients. In approval documents for idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (CARVYKTI), regulators cite overall response rates running from roughly 72 percent up to nearly 98 percent, and they also flag risks such as cytokine release syndrome and neurologic toxicities.
Although CAR-T therapy is an effective treatment for patients with relapsed or refractory multiple myeloma, the treatment carries significant risks, such as cytopenias, infections, and hypogammaglobulinemia. Patients typically transition from specialized centers to community care, a critical period where poor communication can lead to missed prophylaxis and increased infection risk.
The communication study included patients with multiple myeloma who were treated with ide-cel or cilta-cel CAR-T therapies and were referred from community oncology practices. The investigators leveraged the Plan-Do-Study-Act model to analyze whether improved communication enhanced adherence to prophylactic medications and IVIG (intravenous immunoglobulin) use. Data collection included a retrospective chart review of 20 patients performed from August 2023 to June 2024, and a post-intervention review of 9 patients over 8 weeks.
The study intervention included the addition of a standardized prophylaxis grid to a day-30 letter, which was distributed to participants via encrypted email with a receipt request. The outcomes measured included adherence to antiviral or pneumocystis jirovecii pneumonia (PJP) prophylaxis, IVIG administration, and immunoglobulin G (IgG) monitoring, while descriptive statistics were used to compare pre- and post-intervention adherence.
Prophylactic regimen adherence improved significantly after the intervention was implemented. Non-compliance of PJP prophylaxis dropped from 20% to 11%, and IVIG non-compliance decreased from 65% to 22%. These results align with current literature emphasizing the role of clear communication in improving care transitions and adherence.
Published trial reports and expert reviews have found that many patients achieve deep responses and a meaningful subset reach long-term remission, although results vary by product and by patient. Studies of BCMA-directed CAR T therapy have documented complete response rates as high as roughly two-thirds in certain cohorts, and longer follow-up has shown a fraction of patients remaining progression-free at five years.
At Beth Israel Deaconess Medical Center, the Randi and Brian Schwartz Family Cancer Immunotherapy and Cell Manipulation Facility was designed to build and test cell therapies on site, giving teams the ability to engineer CAR T cells and produce experimental vaccines under Good Manufacturing Practice conditions. The on-campus suite and biologics clinic speed up production and let researchers tweak protocols without the delays of offsite manufacturing.
Investigators are also pursuing a complementary path with personalized cancer vaccines that fuse a patient's tumor cells with dendritic cells to expand tumor-reactive immune responses. A multi-site initiative was launched to share vaccine production protocols so that other centers could adopt the approach. At least one early patient who received a cell-based strategy in 2017 stayed in remission for five years.
Oncology nurses play a pivotal role in facilitating handoff communication during transitions in care for patients with relapsed or refractory multiple myeloma. Nurses ensure clear, targeted information exchange that promotes adherence to infectious prophylaxis and IVIG protocols, reducing infection risks and improving outcomes. By customizing handoff tools and coordinating care, nurses enhance communication effectiveness and patient safety in oncology practice.